Jeff Hubbell, PhD

University of Chicago

Pritzker School of Molecular Engineering

Executive Committee Member, Chan Zuckerberg Biohub Chicago

AREA(S) OF FOCUS:

Enhancing the immune system with molecular engineering

The Hubbell lab is developing drugs to reverse autoimmune conditions and enhance the immune response against tumors & infectious diseases.

KEY RESEARCH AREAS:

Immune boosting nanomaterials
Develop nanotechnology to activate immune T-cells against infectious diseases and tumors.

Shaping anti-tumor immunity
Stimulate anti-tumor immunity with nanomaterials carrying toxic molecules into tumors.

Mechanisms of immune tolerance
Investigate the mechanism of self-tolerance to develop drugs that reverse allergies and autoimmune diseases.

Nanomaterials provide a wide variety of uses



ENTREPRENEURIAL SUCCESS:

clostrabio

ClostraBio develops novel ways to treat inflammatory bowel disease (IBD) and food allergies using co-polymers to effectively deliver therapeutics.

The leading asset for IBD is a co-polymer formulation of butyrate, which stabilizes and renders the butyrate odorless.

Series A (2022) - $4 million and raised $11 million overall.

Additional companies include:

Kuros Biosciences

Kuros Biosciences designs biomaterials for surgical sealants and tissue repair and raised $82.2 million.

ANOKION

Anokion develops immune tolerizing technology to reverse autoimmune conditions such as celiac disease, a condition caused by gluten intolerance. Anokion has raised $112.6 million.

Focal Inc.

Focal, Inc., a medical sealant maker was acquired by Genzyme Biosurgery in 2001 for $10M.